Patents
Sitemap › C07 - Organic chemistry › C07K - Peptides › C07K 14 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
Patents for C07K 14 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof (291,526)
12/2005
12/08/2005US20050272029 Hepatitis c viral-like particle purification
12/08/2005US20050272028 Myostatin and mimetics thereof
12/08/2005US20050271690 Glycosyltransferases for biosynthesis of oligosaccharides, and genes encoding them
12/08/2005US20050271689 Novel targets and compositions for use in decontamination, immunoprophylaxis, and post-exposure therapy against anthrax
12/08/2005US20050271688 Modified vaccinia ankara virus variant
12/08/2005US20050271687 Retrovirus-like particles made non-infectious by a plurality of mutations
12/08/2005US20050271686 glycoprotein cationic polypeptide as HIV vaccines; nontoxic
12/08/2005US20050271685 Cellular permissivity factor for viruses and uses thereof
12/08/2005US20050271683 Nucleic acid sequences encoding Ostertagia ostertagi proteins and parts of such nucleic acid sequences encode an immunogenic fragment of such proteins; for use in vaccines
12/08/2005US20050271682 Administering the chimeric protein, comprising at least a first and a second polypeptide, wherein the N-terminus of the chimeric protien comprises the first polypeptide, wherein the first polypeptide comprises Borrelia burgdorferi OspC and wherein second polypeptide comprises Borrelia burgdorferi OspA
12/08/2005US20050271681 Isolated FrpB nucleic acid molecule and vaccine
12/08/2005US20050271680 Using immunogenic proteins LigA and LigB from Leptospira in development of effective vaccines and antibodies; detection of pathogenic Leptospira infection in a mammal
12/08/2005US20050271678 Diagnostic compositions containing the polypeptide conjugated to a detectable label, such as radioisotopes, enzymes, fluorescent labels, antibody conjugates, or substrates
12/08/2005US20050271677 inhibiting Flavivirus infection by inhibiting the fusion between the virion envelope and a cell membrane; E1 envelope glycoprotein of hepaciviruses and E2 envelope glycoprotein of pestivirus have previously undescribed structures, truncated class II fusion proteins
12/08/2005US20050271676 Inducing cellular immune responses to human immunodeficiency virus-1 using peptide and nucleic acid compositions
12/08/2005US20050271675 Includes a hapten or an antigen covalently linked to a carrier; not reversible at physiological pH, and that do not require reduction with boron-hydride
12/08/2005US20050271670 Treatments for cancer
12/08/2005US20050271667 Identification of a novel endothelial-derived gene EG-1
12/08/2005US20050271662 Proteins, polypeptides, fusion proteins, polynucleotides, vectors, host cells, antibodies or antigen binding portions; diagnosis and treatment of canine or feline B-cell lymphoma, immune-mediated hemolytic anemia or thrombocytopenia, and systemic lupus erythematosus
12/08/2005US20050271659 Novel T-cell membrane protein (TIRC7), peptides and antibodies derived therefrom and uses thereof
12/08/2005US20050271656 Methods for designing specific ion channel blockers
12/08/2005US20050271655 Nogo receptor antagonists
12/08/2005US20050271646 Fibrin material and method for producing and using the same
12/08/2005US20050271642 Genetically engineering organisms that produce proteins lethal to larvae of insects nucleotide sequences isolated from Bacillus popilliae encode two adjacent, putative genes; orf1 and cryhime; insecticides, larvicides, pesticides; beetles
12/08/2005US20050271638 BMP pathway methods and compositions
12/08/2005US20050271637 BMP-2 estrogen responsive element and methods of using the same
12/08/2005US20050271636 Diagnostic and therapeutic uses for prox 1
12/08/2005US20050271628 Negative-sense RNA virus vector for nerve cell
12/08/2005US20050271627 Calbindin-D28K protection against glucocorticoid induced cell death
12/08/2005US20050271623 Reduction of dermal scarring
12/08/2005US20050271622 Construct of tumor-selective recombinant adenovirus, method for preparing the same and use thereof
12/08/2005US20050271621 Ablated slam-dependent entry
12/08/2005US20050271620 Herpes simplex virus complex
12/08/2005US20050271618 Methods of reducing aggregation of IL-1ra
12/08/2005US20050271614 Type V telopeptide-containing collagen protein combined with a drug that may be an antibiotic, an anti-fungal, an anti-dandruff agent, an anti-itch agent, a sunburn treatment agent, an acne treatment agent or an wrinkle-minimizing agent.
12/08/2005US20050271592 Optical diagnostic and therapeutic agents and compositions
12/08/2005US20050271589 For therapy of cancer; for therapy of disorders associated with voltage-gated ion channels, ligand gated channels and other receptors
12/08/2005DE102004022435A1 Verfahren zur Herstellung löslicher MHC-Proteine Process for the preparation of soluble MHC proteins
12/08/2005CA2822895A1 Influenza hemagglutinin and neuraminidase variants
12/08/2005CA2777821A1 Mhc molecule-binding tumor-associated peptides
12/08/2005CA2569003A1 Methods and compositions for cancer treatment relating to brca1 brct domain recognition of phosphorylated bach1
12/08/2005CA2568363A1 Natriuretic compounds, conjugates, and uses thereof
12/08/2005CA2568254A1 Tumor-associated peptides that bind to mhc-molecules
12/08/2005CA2568201A1 Identification of ergothioneine transporter and therapeutic uses thereof
12/08/2005CA2568020A1 Influenza hemagglutinin and neuraminidase variants
12/08/2005CA2568015A1 Influenza hemagglutinin and neuraminidase variants
12/08/2005CA2567952A1 Oral anti-protozoiasis vaccines based on transgenic plants
12/08/2005CA2567942A1 Hla-a24- or hla-a2-binding peptide of parathyroid hormone-related protein
12/08/2005CA2567814A1 Antibodies as t cell receptor mimics, methods of production and uses thereof
12/08/2005CA2567478A1 Labelled adrenomedullin derivatives and their use for imaging and therapy
12/08/2005CA2566572A1 Gene-cassette for enhancement of protein production
12/08/2005CA2566481A1 Peptides or peptidic conjugate derivatives of msh and the use thereof for cosmetically fighting against canities
12/08/2005CA2566478A1 Alpha-msh-antagonist didpeptide conjugates
12/08/2005CA2565886A1 Treatment of inflammatory airway disease
12/08/2005CA2565805A1 Msh-agonist tripeptide conjugates
12/08/2005CA2565794A1 Endothelial cell apoptosis induced by fibrinogen gamma chain c-terminal fragment
12/08/2005CA2565330A1 Polypeptides for inducing a protective immune response against staphylococcus aureus
12/08/2005CA2565259A1 Soluble lfa-3 polypeptide for treating viral disorders
12/08/2005CA2565098A1 Treatment of neurodegenerative disease through intracranial delivery of sirna
12/08/2005CA2564114A1 Pdx1 expressing endoderm
12/08/2005CA2563999A1 Keratin-binding polypeptides
12/08/2005CA2563374A1 Antagonism of tgf-.beta.superfamily receptor signaling
12/08/2005CA2562037A1 Altered fibronectin-binding protein of staphylococcus aureus
12/08/2005CA2553826A1 Neoplasm-specific polypeptides and their uses
12/07/2005EP1602930A2 Use of compounds that bind to GPR49 for diagnosis and treatment of cancer
12/07/2005EP1602926A1 Novel means and methods for the treatment of hearing loss and phantom hearing
12/07/2005EP1602732A2 Nucleic acid mutation detection by analysis of sputum
12/07/2005EP1602726A2 Human tachykinin-related splice variants and compositions thereof
12/07/2005EP1602720A1 Process for producing foreign protein in escherichia coli
12/07/2005EP1602718A1 Neutral phenol oxidase
12/07/2005EP1602717A1 Plant and plant cell having been modified in cell multiplication and development/differentiation
12/07/2005EP1602668A1 Monoclonal antibodies specific to VEGF receptors and uses thereof
12/07/2005EP1602667A1 Aqueous formulation comprising TFPI and solubilising agents
12/07/2005EP1602666A1 Novel protein and its dna
12/07/2005EP1602665A1 Physiologically active peptides and drugs containing the same
12/07/2005EP1602664A1 HCV E1 comprising specific disulfide bridges
12/07/2005EP1602380A1 Preventive/remedy for diseases in upper digestive tract
12/07/2005EP1602379A1 Botulinum toxin B for treating spastic muscle
12/07/2005EP1601797A1 Diagnostic and prognostic compounds and method
12/07/2005EP1601776A2 Expression vectors comprising the mcmv ie2 promoter
12/07/2005EP1601775A1 Animal model for the fast identification of pharmaceutical active compounds in vivo
12/07/2005EP1601771A1 Subunits of the adenovirus fiber protein and uses thereof as vaccines
12/07/2005EP1601770A2 Streptococcus pyogenes antigens
12/07/2005EP1601769A1 Papillosin antimicrobial peptide, a gene for coding said peptide, a vector, a transformed organism and a compound containing said organism
12/07/2005EP1601768A2 Anti-microbial peptide known as halocyntin, gene coding for said peptide, vector, transformed organism and composition containing said peptide
12/07/2005EP1601766A1 Methods of constructing biodiverse gene fragment libraries and biological modulators isolated therefrom
12/07/2005EP1601762A1 Extraction and use of collagen extracted from either a sea mammal or a bony fish
12/07/2005EP1601758A2 Polynucleotides and polypeptides in plants
12/07/2005EP1601698A1 Physiologically active polypeptide conjugate having prolonged in vivo half-life
12/07/2005EP1601697A1 Antibody purification by Protein A and ion exchange chromatography
12/07/2005EP1601696A1 Compositions and methods for inhibiting inflammation of vessel walls and formation of neointimal hyperplasia
12/07/2005EP1601695A1 Mcam inhibitors
12/07/2005EP1601694A2 Uses of il-23 agonists and antagonists; related reagents
12/07/2005EP1601693A2 Novel compositions and methods for the treatment of immune related disease
12/07/2005EP1601692A2 Enzymes involved in apoptosis
12/07/2005EP1601691A2 Shrew paralytic peptide for use in neuromuscular therapy
12/07/2005EP1601689A2 Purification process for bacterial cytolysin
12/07/2005EP1601688A2 Genes of an otitis media isolate of nontypeable haemophilus influenzae
12/07/2005EP1601684A2 Compositions and methods employing alternative reading frame polypeptides for the treatment of cancer and infectious disease
12/07/2005EP1601642A2 Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex
1 ... 1116 1117 1118 1119 1120 1121 1122 1123 1124 1125 1126 1127 1128 1129 1130 1131 1132 1133 1134 1135 1136 ... 2916